Acadia Pharmaceuticals | ACAD - 现金及等价物



金融业
股票价格
USD
资产
USD 1.61B
现金及等价物
USD 851.46M
销售成本
USD 24.79M
流动资产
USD 1.1B
流动负债
USD 305.52M
债务
USD 52.19M
EBIT
USD -4.62M
EBITDA
USD 20.32M
员工
653
EPS每股收益
USD 0.02
股本和储备
USD 1.25B
销售毛利
USD 243.27M
债务利息支出
USD 0
利息收入
USD 8.33M
贷款资金
USD 0
市值
USD 3.51B
净收入
USD 3.64M
营业费用
USD 272.68M
营业利润
USD -4.62M
普通股股本
USD 169.18M
PE价格收益
10.08
税前利润
USD 3.98M
销售收入
USD 268.06M
销售和管理费用
USD 160.79M
股票
USD 31.57M
贸易债权人
USD 12.25M
应收帐款人
USD 148.38M


现金及等价物 更改 日
Acadia Pharmaceuticals USD 851.46M 31.77M 2026-03
ALKERMES USD 351.55M 37.02M 2026-03
Alnylam Pharmaceuticals USD 1.71B 53.53M 2026-03
Biogen USD 3.38B 374.2M 2026-03
BioMarin Pharmaceutical USD 2.22B 910.76M 2026-03
Bristol-Myers Squibb USD 9.57B 635M 2026-03
Cara Therapeutics USD 20.73M 684K 2025-12
Corcept Therapeutics USD 108.74M 11.76M 2026-03
Cytokinetics USD 129.84M 7.32M 2026-03
Eisai JPY 301.65B 16.27B 2025-09
Eli Lilly USD 5.28B 1.99B 2026-03
Incyte USD 4.02B 435.22M 2026-03
J&J USD 21.69B 1.98B 2026-03
Moderna USD 1.91B 687M 2026-03
Neurocrine Biosciences USD 266.5M 446.5M 2026-03
Pfizer USD 1.7B 561M 2026-03
Prothena USD 329.46M 21.93M 2026-03
PTC Therapeutics USD 833.99M 150.66M 2026-03
Sarepta Therapeutics USD 464.45M 336.83M 2026-03
Ultragenyx Pharmaceutical USD 175M 246M 2026-03
Vanda Pharmaceuticals USD 84.85M 14.83M 2025-12
Vertex Pharmaceuticals USD 7.25B 638.6M 2026-03